The industry’s focus is on living organisms, and the strict controlled standards make it a distinct consideration for business executives. These aspects make the sector an ideal incubator for innovation. They have resulted in major breakthroughs in agricultural yields, biofuels, and life-saving pharmaceuticals.
Start-up biotech companies have many options for revenue generation strategies, with the majority choosing either a technology partnering or an approach to asset creation and out-licensing. Technology partnering generates faster revenue with lower financial risk while an asset creation and out-licensing strategy can yield significantly more lucrative returns if it is successful. A growing number of biotechs at the research stage use in a hybrid approach that combines both strategies.
People who choose a product-oriented development strategy can achieve commercial success when they get their pipeline to the appropriate stage and then attract a major pharmaceutical partner or an investor with deep pockets. This is expensive however, and the balance of opportunistic strategies to leverage external resources with scientific decisions about homegrown projects is crucial.
The «platform» model is an alternative alternative to generate revenue. It is less expensive than development based on product, but comes with a high risk. In this model, a biotech owns and develops its platform technology prior to partnering with big pharma companies to generate a portfolio of drug discovery projects that are targeted at specific disease areas (i.e., disease x in biology y). Advinus Therapeutics, among others have adopted this strategy.
www.genotec-frankfurt.de/biotechnological-synthesis-of-remedies/